Abivax appoints Ida Hatoum as Chief People Officer – Biotech Investments

Abivax appoints Ida Hatoum as Chief People Officer

As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions

Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry

PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Ida Hatoum as Chief People Officer. Ida will be responsible for Abivax’s growth strategy in the United States and Europe, ensuring the appropriate staffing of the Company to successfully conduct the ongoing Phase 3 clinical program of obefazimod in ulcerative colitis as well as its subsequent commercialization and market access, provided the drug candidate obtains the required regulatory approvals. Ida will be based at Abivax’s subsidiary on the US East Coast.

Ida Hatoum brings over 15 years of experience and a strong track record in talent acquisition and development and has occupied different People Operations leadership positions in the pharmaceutical and biotechnology industry. Prior to joining Abivax, Ida was Senior Vice President and Head of People Talent and Culture at CinCor Pharma, where she successfully managed and lead the recruitment strategy and organizational design of the company during a period of strong growth. Ida holds a bachelor’s in pharmacy from the University of Toledo, Ohio.

Marc de Garidel, CEO of Abivax, said: “I am glad to welcome Ida to the Abivax team as she will be leading our global recruitment strategy. Her vast experience in talent acquisition and development will be vital for us to complement our current team with new competent and dedicated colleagues who share our commitment of bringing novel and potent therapeutic alternatives to patients in need.”

Ida Hatoum, new Chief People Officer of Abivax, added: “I am thrilled to join the Abivax team during this exciting period of strong growth and internationalization and to contribute to the success of the Company, establishing a global team and a common company culture. I am convinced that the Abivax story will enable us to further attract highly qualified and motivated new colleagues across the different functions to successfully bring the very promising drug candidate obefazimod to the market and the patients.”

*****

About Abivax (www.abivax.com)

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company’s programs. Although Abivax’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d’Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.